Are Germline DNA Repair Mutations Linked to Outcomes in mCRPC?
A new study published in the Journal of Clinical Oncology reported on the clinical implications of gDDR genes.
Role of the ALK Inhibitor AZD3463 in Sorafenib-Resistant Acute Myeloid Leukemia
Investigators evaluated whether AZD3463 can induce apoptosis in a dose-dependent manner in a subset of AML patients.
Study Investigates Diverse Molecular Mechanisms Driving Treatment Resistance in AML
Researchers evaluated the primary mechanisms governing drug resistance and relapse in patients treated with crenolanib, an FLT3 inhibitor.
Study Investigates Survival Rates in Patients with Medullary Thyroid Carcinoma
Researchers conducted the first population-based study of an unselected MTC cohort compared with the general population.
Utilizing US Features and BRAFV600E Mutation Status to Stratify Papillary Thyroid Carcinoma
Clinicians may be able to utilize this information as an effective preoperative tool to stratify risk and determine an initial surgical approach for patients with PTC.
Risk of Future Cancers in Survivors of Childhood Hodgkin Lymphoma
Guidelines for cancer screening in survivors of childhood HL may be refined based on the results of this extended follow-up study, say the researchers.
Is the Revised ELN Classification More Accurate for Acute Myeloid Leukemia?
A new study published in Cancer compared ELN-2017 to ELN-2010 in terms of distinguishing prognosis in younger patients with newly diagosed AML.
Study Evaluates Addition of Glasdegib in AML and High-Risk MDS Patients
Researchers reported on the impact of adding the Hedgehog pathway inhibitor glasdegib to low-dose cytarabine.
Chemotherapy in NSCLC Patients With COPD: Do Benefits Outweigh the Risks?
Researchers investigated whether first-line chemotherapy improved overall survival in NSCLC patients with severe to very severe COPD.
Newly Approved Agent Fills Gap in Therapy for High-Risk AML
The US Food and Drug Administration recently approved a new agent for treatment of adult patients with relapsed or refractory acute myeloid leukemia.
First Hedgehog Pathway Inhibitor Approved in AML Patients
Clinicians now have a new treatment to offer elderly patients with newly diagnosed acute myeloid leukemia who have comorbidities that preclude the use of intensive chemotherapy.
Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC
Researchers evaluated the survival benefit of adding pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab–paclitaxel compared with chemotherapy alone.
Which Approach is Best for Biopsy Gleason Score 9–10 Prostate Cancer?
A recent study in JAMA Oncology compared survival for various multi-modality approaches for treating aggressive prostate cancer.
Higher Gleason Score and ADT Efficacy: Examining the Link in Prostate Cancer
Researchers examined whether a higher Gleason score impacts the efficacy of androgen deprivation therapy.
The Verdict on IMRT Plus Doxorubicin in Unresectable Thyroid Cancer
A study in Thyroid evaluated the safety and efficacy of concurrent intensity-modulated radiation therapy and doxorubicin in thyroid cancer.
Is First-Line Avelumab Effective for Metastatic Merkel Cell Carcinoma?
Investigators shared results of an interim analysis evaluating antitumor activity and safety in patients with mMCC receiving avelumab monotherapy.
New Study Looks at Selumetinib for Treating Differentiated Thyroid Cancer
Interim results are in from a study evaluating whether adding selumetinib to RAI improves complete response, irrespective of MAPK pathway alterations.
Is ADT Linked to Dementia in Men with Prostate Cancer Receiving Definitive Radiotherapy?
The findings of this study, recently published in JAMA Oncology, directly contradict previously conducted research on the same topic.
New Expert Guidance on EBRT in Men with Early-Stage Prostate Cancer
Oncologists now have some clarification on the use of moderate hypofractionation and ultrahypofractionation from ASTRO, ASCO, and the AUA.
Is Controversy Over NCRT Plus Surgery Warranted in Esophageal Squamous Cell Carcinoma?
A new study adds to evidence examining whether neoadjuvant chemoradiotherapy plus surgery improves survival vs surgery alone in locally advanced ESCC.
Are We Underdosing Patients With Ewing Sarcoma?
A new study evaluated whether busulfan and melphalan improve EFS and OS when given after vincristine, ifosfamide, doxorubicin, and etoposide induction.
Significance of MHC-II in Immunotherapy
While previous research has proven the role of MHC-I molecules, a new study in Cell suggests that MHC-II may also serve as a target in immunotherapy.
Fatal Toxicities Vary by Immune Checkpoint Inhibitor Type
A study in JAMA Oncology found that a wide range of fatal toxic events can occur with immune checkpoint inhibitors, and the type of event varies by agent.
The Link Between Apalutamide and QOL in Non-Metastatic CRPC
New research in Lancet Oncology confirms previous studies in this population on the addition of apalutamide to androgen deprivation therapy.
Radical Prostatectomy Plus Radiotherapy Extends OS in Prostate Cancer
A study in Cancer found a lower risk of prostate cancer–specific death and improved overall survival when patients were treated with this combination.
ANO7 Gene Linked to Aggressive Prostate Cancer
By elevating the expression of ANO7, a potential prostate cancer susceptibility gene, it may be possible to predict disease severity and outcome.
Basal Cell Carcinomas a Clinical Marker for Malignancy Risk?
Individuals who develop frequent basal cell carcinomas may have an increased prevalence of germline mutations in DNA repair genes and an increased malignancy risk.
Chromosomal Abnormality May Hold Promise in Treating AML
Although the study found lurbinectedin isn't promising, the presence of a chromosomal 11q21-23 abnormality may open doors in treating the disease.
Nuclear Pore Proteins May Be Effective Anti-Cancer Targets for Prostate Cancer
A particular gatekeeper-the nuclear pore protein called POM121-traffics molecules that increase tumor aggressiveness in prostate cancer.
Corticosteroids at Time of PD-L1 Blockade May Reduce Efficacy in NSCLC
Taking corticosteroids at the time of treatment initiation with PD-L1 inhibitors may lead to inferior outcomes in patients with non–small-cell lung cancer.